Close

Novartis (NVS) Said in Talks to Buy Amneal Pharma - Bloomberg

Go back to Novartis (NVS) Said in Talks to Buy Amneal Pharma - Bloomberg

Novartis (NVS) Announces AMG 334 Phase 3 Met Primary Endpoint as Migraine Treatment

November 16, 2016 4:35 PM EST

Novartis (NYSE: NVS) announced positive topline results from the global Phase III STRIVE study, evaluating the efficacy and safety of the fully human monoclonal antibody AMG 334 (erenumab) in episodic migraine prevention. Once-monthly subcutaneous AMG 334 was evaluated at 70mg and 140mg doses, with both doses meeting the study's primary endpoint, demonstrating a statistically significant reduction from baseline in mean monthly migraine days at six months versus placebo.[1] AMG 334 is specifically designed to target and block the Calcitonin Gene-Related Peptide (CGRP) receptor that is believed to have a critical role in mediating the incapacitating... More